- Home
- SGN vs RDHL Comparison
SGN vs RDHL Comparison
Compare SGN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGN | RDHL |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGN | RDHL |
|---|---|---|
| Price | $0.96 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 84.1K | 71.8K |
| Earning Date | 11-12-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $366,344.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.44 | $0.91 |
| 52 Week High | $7.24 | $6.80 |
Technical Indicators
Market Signals| Indicator | SGN | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 38.43 |
| Support Level | $1.11 | $0.91 |
| Resistance Level | $1.13 | $1.23 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.90 | 46.21 |
Price Performance
Historical ComparisonAbout SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.